Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkins lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkins lymphoma, non-small cell lung cancer and esophageal cancer.
Purity:
95.00%
CAS Number:
[2072873-06-2]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted
